Clinical Trial Update: Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial results for FAB122, a daily oral edaravone formulation, in amyotrophic lateral sclerosis have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• FAB122 (Daily Oral Edaravone) (edaravone)

Snippet

Sponsor: Ferrer Internacional S.A. | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2025-03-18